目的:分析冠心病合并高脂血症患者接受瑞舒伐他汀治疗后血脂和内皮细胞功能的变化。
方法:回顾性纳入2020年12月至2021年12月确诊的120例冠心病合并高脂血症患者。根据他们治疗策略的不同,将患者分为研究组(60例患者采用瑞舒伐他汀常规治疗)和对照组(60例患者采用常规治疗)。对两组患者进行动态血脂水平监测。评价治疗前后心功能及血液流变学指标的变化。分析两组治疗前后血管内皮功能指标的差异。统计两组患者干预期间不良反应发生情况。
结果:治疗前,两组总胆固醇(TC)无显著差异,甘油三酯(TG),低密度脂蛋白(LDL-C),左心室射血分数(LVEF),左心室收缩末期内径(LVDS),左心室舒张末期内径(LVEDD),纤维蛋白原含量,血浆粘度,一氧化氮(NO),内皮素(ET)水平(P>0.05)。治疗60天后,两组间TC无显著差异,TG,LDL-C,LVDS,和LVEDD。纤维蛋白原含量,血浆粘度,内皮素水平低于对照组(P<0.05)。HDL-C,LVEF,观察组NO水平高于对照组(P<0.05)。两组不良反应总发生率(8.33%vs13.33%)差异无统计学意义(P>0.05)。
结论:瑞舒伐他汀可降低冠心病合并高脂血症患者的血脂水平,改善患者的血液流变学指标和心功能。其机制可能与冠心病患者血管内皮细胞功能的调节有关。
OBJECTIVE: To analyze the changes of blood lipids and endothelial cell function in patients with coronary heart disease complicated with hyperlipidemia after treatment with rosuvastatin.
METHODS: A total of 120 patients with coronary heart disease and hyperlipidemia diagnosed from December 2020 to December 2021 were retrospectively included. Depending on the differences of their treatment strategies, patients were divided into the study group (60 patients were treated with rosuvastatin using the conventional treatment) and the control group (60 patients were treated with the conventional treatment). Dynamic blood lipid level monitoring was performed on the two groups of patients. The changes of cardiac function and hemorheology indexes were evaluated before and after the treatment. Analyze the difference of vascular endothelial function index between the two groups before and after the treatment. Count the occurrence of adverse reactions during the intervention period of the two groups.
RESULTS: Before the treatment, there was no significant difference between the two groups in total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVDS), left ventricular end-diastolic diameter (LVEDD), fibrinogen content, plasma viscosity, nitric oxide (NO), and endothelin (ET) levels (P>0.05). At 60 days of treatment, there was no significant difference between the two groups in TC, TG, LDL-C, LVDS, and LVEDD. The fibrinogen content, plasma viscosity, and ET level were lower than those in the control group (P<0.05). The HDL-C, LVEF, and NO levels were higher than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (8.33% vs 13.33%) (P>0.05).
CONCLUSIONS: Resuvastatin can reduce the level of blood lipids in patients with coronary heart disease and hyperlipidemia and improve the hemorheology indexes and cardiac function of patients. Its mechanism may be related to the regulation of vascular endothelial cell function in patients with coronary heart disease.